Bringing doctors together

or

A free, private network for verified physicians

Leading voices

Dr. Dana Chase

Gyn Onc · UCLA

View

Dr. Kimberly Resnick

Gyn Onc · MetroHealth

View

Dr. Ashley Stuckey

Gyn Onc · Women & Infants Hospital

View

Dr. Susan Khalil

MIGS · ISMMS

View

Dr. Tori O’Daniel

OB Hospitalist · Laborie-MCH division, Senior Medical Director

View

Dr. Alissa Erogbogbo

OB Hospitalist · Washington Health System

View

Dr. Christina Adams

OB Hospitalist · Flagler Hospital

View

Dr. Brigid McCue

OB Hospitalist · Northwell Health

View

Dr. Bruce Bekkar

General OBGYN · ecoAmerica

View

Dr. Jennifer Lincoln

OB Hospitalist · Providence

View
  • Discover your community

  • Stay current

  • A profile that represents you

  • Find your people

About RoonPrivacyTerms

    Overview

    Detection of Residual Peritoneal Metastases Following Cytoreductive Surgery Using Pegsitacianine, a pH-Sensitive Imaging Agent: Final Results from a Phase II Study.

    Apr 15, 2024DOI: 10.1245/s10434-024-15165-4Journal ArticleASO

    Written by: Patrick WagnerEdward A LevineAlex C KimPerry ShenNicole D FlemingShannon N WestinLaurel K BerryGiorgos C KarakousisJanos L TanyiMadeline T OlsonBrian MadajewskiBrian OstranderKartik KrishnanCharles M BalchDavid L Bartlett

    Find these authors on Roon

    LB
    Dr. Laurel Berry
    Gyn Onc · Bowman Gray School of Medicine

    Summary

    BACKGROUND: For patients with peritoneal carcinomatosis, extent of disease and completeness of cytoreductive surgery (CRS) are major prognostic factors for long-term survival. Assessment of these factors could be improved using imaging agents. Pegsitacianine is a pH-sensitive polymeric micelle conjugated to the fluorophore indocyanine green. The micelle disassembles in acidic microenvironments, such as tumors, resulting in localized fluorescence unmasking. We assessed the utility of pegsitacianine in detecting residual disease following CRS.PATIENTS AND METHODS: NCT04950166 was a phase II, non-randomized, open-label, multicenter US study. Patients eligible for CRS were administered an intravenous dose of pegsitacianine at 1 mg/kg 24-72 h before surgery. Following CRS, the peritoneal cavity was reexamined under near-infrared (NIR) illumination to evaluate for fluorescent tissue. Fluorescent tissue identified was excised and evaluated by histopathology. The primary outcome was the rate of clinically significant events (CSE), defined as detection of histologically confirmed residual disease excised with pegsitacianine or a revision in the assessment of completeness of CRS. Secondary outcomes included acceptable safety and pegsitacianine performance.RESULTS: A total of 53 patients were screened, 50 enrolled, and 40 were evaluable for CSE across six primary tumor types. Residual disease was detected with pegsitacianine in 20 of 40 (50%) patients. Pegsitacianine showed high sensitivity and was well tolerated with no serious adverse events (SAEs). Transient treatment-related, non-anaphylactic infusion reactions occurred in 28% of patients.CONCLUSIONS: Pegsitacianine was well tolerated and facilitated the recognition of occult residual disease following CRS. The high rate of residual disease detected suggests that the use of pegsitacianine augmented surgeon assessment and performance during CRS.
    LBDr. Laurel Berry

    Dr. Laurel Berry

    Obstetrics & Gynecology (OBGYN) · Gynecologic Oncology
    Atrium Health Wake Forest Baptist
    laurel